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Abstract We investigated the longitudinal relationships
between inflammation markers and the following outcomes
in a UK cohort study: appendicular lean mass (ALM);
walking speed; level and change in grip strength; and
sarcopenia defined by the European Working Group on
Sarcopenia in Older People. Analyses were based on 336
community-dwelling older men and women (aged
59–70 years) who participated in the Hertfordshire Cohort
Study (HCS). Inflammation markers were ascertained at
baseline using enzyme-linked immunosorbent assay tech-
niques and Bio-Plex Pro Assays. Grip strength was mea-
sured at baseline and follow-up [median follow-up time:
10.8 years (inter-quartile range 10.2–11.6)] and change in
grip strength was ascertained using a residual change
approach. At follow-up, ALM was ascertained using dual-
energy X-ray absorptiometry, customary walking speed
was measured and sarcopenia status was ascertained.
Gender-adjusted linear and Poisson regression was used to
examine the associations between inflammation markers
and outcomes with and without adjustment for anthropo-
metric and lifestyle factors. Higher C-reactive protein was
associated (p\ 0.04) with lower grip strength and accel-
erated decline in grip strength from baseline to follow-up.
Higher cortisol was associated with lower ALM
(p\ 0.05). Higher interleukin-8 (IL-8) was associated with
lower ALM (p\ 0.05) and increased risk of sarcopenia
[fully-adjusted relative risk per SD increase in IL-8: 1.37
(95% CI 1.10, 1.71), p = 0.005]. All associations were
robust in fully-adjusted analyses. Inflammation markers
were associated with measures of muscle mass, strength
and function in HCS. Further work is required to replicate
these associations and to delineate the underlying
mechanisms.
Keywords Inflammation  Muscle  Sarcopenia  Strength 
Adipokine  Interleukin
Introduction
Sarcopenia is an age-related syndrome characterised by
loss of skeletal muscle mass and strength. It is a major
contributor to the risk of physical frailty, functional
impairment, poor health-related quality of life, and pre-
mature death in older people [1]. The prevalence varies [2]
and it is associated with an estimated annual cost of £2.5
billion to the UK health economy [3].
Previous evidence supports the assertion that immunose-
nescence leads to a chronic, low-grade inflammatory state
which contributes to cellular ageing, and an increased sus-
ceptibility to infection, autoimmunity and neoplasia [4]. A
relationship may exist between inflammation and muscular
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ageing through a process of catabolism and skeletal muscle
atrophy [5].
Interleukin-6 (IL-6), interleukin-1 receptor (IL-1R),
tumour necrosis factor (TNF) and C-reactive protein (CRP)
are primary elements in the inflammatory cascade which
have been associated with disability [6], poor physical
performance [7], reduced muscular strength [8] and muscle
mass [9]. However, a recent meta-analysis of the rela-
tionship between three markers of inflammation and sar-
copenia only showed a relationship with CRP but none
with TNF or IL-6 [10]. This inconsistency highlights the
need for further research which investigates the relation-
ships between a wider range of inflammatory markers and
sarcopenia.
The Hertfordshire Cohort Study (HCS) [11] provides an
excellent opportunity to investigate these associations
among a population-based cohort of community-dwelling
older men and women from the United Kingdom.
The objective of this study was to investigate the longi-
tudinal associations between a wide range of markers of
inflammation and the following outcomes among HCS
participants: appendicular lean mass (ALM), walking speed,
level and change in grip strength, and sarcopenia defined
according to the European Working Group on Sarcopenia in
Older People (EWGSOP) consensus algorithm [1].
Methods
The Hertfordshire Cohort Study
The HCS comprises 1579 men and 1418 women born in
Hertfordshire between 1931 and 1939 and who still lived
there in 1998–2004 when they completed a baseline home
interview and attended a research clinic for detailed char-
acterisation of their socio-demographic, lifestyle and clin-
ical characteristics; the study has been described in detail
previously [11].
Smoking status, weekly consumption of alcohol and
level of physical activity (Dallosso questionnaire [12])
were ascertained by a nurse-administered questionnaire at
the home interview. Participants completed a food-fre-
quency questionnaire from which a ‘prudent diet’ score
was derived using principal components analysis; higher
scores reflect healthier diets [13]. Details of all prescription
and over-the-counter medications currently taken were
coded according to the British National Formulary; the
number of systems medicated was used as a marker of
comorbidity.
Investigations conducted at the baseline clinic included
measurement of height (using a Harpenden pocket sta-
diometer, Chasmors Ltd, London, UK) and weight (on a
SECA floor scale, Chasmors Ltd, London, UK). Grip
strength was assessed three times for each hand using a
Jamar dynamometer; the highest measurement was used
for analysis. Blood samples were taken and serum was
aliquoted and stored at - 80 C.
Overall, 966 participants resident in East Hertfordshire
underwent a dual-energy X-ray absorptiometry (DXA)
scan at baseline. In 2004, 642 of them were recruited to a
musculoskeletal follow-up study. In 2011, 591 were invited
to participate in a further follow-up study; 443 agreed to
participate [median follow-up time from baseline
10.8 years (inter-quartile range 10.2–11.6)] [14]. Grip
strength and height were measured using the same protocol
as at baseline, mean customary walking speed in metres per
second was ascertained using the mean time from two 8ft
gait speed tests, and ALM was derived using DXA (Lunar
Prodigy Advanced Scanner, GE Medical Systems, UK).
The HCS analysis sample for this paper comprised 336
participants who: had attended the 2011 follow-up stage of
HCS, had non-missing data for at least one of the inflam-
mation markers considered; and had at least one non-
missing value for each of the outcomes. A flow diagram for
the HCS analysis sample is presented in Fig. 1.
Ascertainment of Baseline Inflammatory Markers
Serum cortisol, dehydroepiandrosterone sulphate (DHEAS)
and CRP levels were measured by enzyme-linked
immunosorbent assay (ELISA) techniques using a com-
mercial kit (IBL international, Hamburg, Germany)
according to manufacturer’s instructions. Plasma adipo-
nectin (serum diluted 1:5000) and leptin (serum diluted
1:2000) were assessed separately by solid phase sandwich
ELISA (R&D Systems, Abingdon, UK). Data analysis was
done using GraphPad Prism software (GraphPad Software
Ltd, USA).
A multiplex based assay for the cytokines interleukin-10
(IL-10), interleukin-8 (IL-8), IL-6 and TNF (Bio-Rad
Laboratories, Munich, Germany) was performed according
to manufacturer’s instructions. Data acquisition and anal-
ysis was conducted using Bio-Plex Manager software
version 6.0.
Derived Measures
Height and weight were highly correlated (r = 0.43,
p\ 0.001 for men; r = 0.39, p\ 0.001 for women); to
avoid multi-collinearity problems, a sex-specific standard-
ised residual of weight-adjusted-for-height at baseline was
derived. Conditional change in grip strength was charac-
terised by residuals obtained after estimating sex-specific
linear regression models for grip strength at follow-up on
grip strength at baseline with adjustment for individual
follow-up duration; this measure of change is independent
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of baseline level. Appendicular lean mass index was cal-
culated by dividing ALM (kg) by the square of height (m).
Sarcopenia status at follow-up was derived using the
EWGSOP sarcopenia algorithm [2] with the following cut-
points: ALM index (ALM/height2) B 7.23 kg/m2 for men
(B 5.67 kg/m2 for women); grip strength\ 30 kg for men
(\ 20 kg for women); and walking speed B 0.8 m/s. Par-
ticipants with slow walking speed or weak grip strength,
and who also had low ALM index were classed as
sarcopenic.
Statistical Methods
Summary statistics were used to describe the data. Apart
from IL-8, all inflammatory markers were highly positively
skewed and were log-transformed. Linear regression was
used to examine the longitudinal association between each
baseline inflammatory marker and the following continu-
ous outcomes: walking speed, grip strength and ALM at
follow-up; and conditional change in grip strength from
baseline to follow-up. The association between baseline
inflammatory markers and sarcopenia status at follow-up
was examined using Poisson regression models with robust
variance estimation to yield relative risks. Gender-adjusted
and fully-adjusted models, which also accounted for gen-
der, baseline age, follow-up time, height, weight-for-
height, smoking history, alcohol consumption, prudent diet
score and physical activity were implemented.
Sex-specific standard deviation scores were coded for
inflammatory markers and outcomes and used in models.
To maintain sample size, men and women were pooled and
analyses were adjusted for gender; p\ 0.05 was regarded
as statistically significant. Analyses were conducted using
Stata, release 13.
Results
Participant Characteristics
Characteristics of the 336 HCS participants who were
included in the analysis sample are presented in Table 1.
Mean (SD) age at HCS baseline was 63.8 (2.5) and 65.6
(2.7) years among men and women, respectively. Median
(inter-quartile range) time from HCS baseline clinic to the
2011 follow-up was 11.6 (11.1, 11.9) years among men and
10.1 (9.8, 10.4) years among women. On average, men had
higher ALM and faster walking speed compared with
women. On average, men had much higher grip strength
than women at both baseline and follow-up but experi-
enced greater annual loss of grip strength (mean (SD)
change in grip among men and women, respectively:
- 0.71 (0.48) kg/year vs - 0.58 (0.49) kg/year).
Assessing Healthy Participant Effects in Analysis
Sample
Compared to the 2661 participants who attended the HCS
baseline clinic but were not included in the analysis sam-
ple, both men and women in the analysis sample had higher
self-reported activity (Dallosso questionnaire); diet quality
was higher among women only (p\ 0.003 for both).
However, smoking prevalence, alcohol consumption and
the proportion who were of manual social class (classes
Fig. 1 Flow diagram for the Hertfordshire Cohort Study analysis
sample
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IIIM, IV and V from the 1990 Office of Population Cen-
suses and Surveys (OPCS) Standard Occupational Classi-
fication (SOC90) unit group for occupation [15]) did not
differ significantly (p[ 0.05) between the two groups; this
was the case among men and women.
Compared to the 107 participants who were invited to
participate in the follow-up study in 2011 but were not
included in the analysis sample, men in the analysis sample
had higher self-reported activity (p = 0.01); there were no
differences in other health behaviours or occupation class
among men or among women.
Associations Between Baseline Inflammation
Markers and Muscle Mass, Strength and Function
at Follow-Up
Associations between baseline inflammation markers and
the following outcomes are presented in Table 2 and
Fig. 2: grip strength, walking speed, ALM and sarcopenia
status at follow-up; and conditional change in grip from
baseline to follow-up. In gender- and fully-adjusted anal-
yses, higher CRP was associated with lower grip strength,
accelerated loss of grip strength, and higher ALM. For
example, an SD increase in CRP was associated with an
average reduction in grip strength level of 0.21 (95% CI
0.10, 0.32) SDs. Higher CRP and lower adiponectin:leptin
ratios were each associated with slower walking speed in
gender-adjusted analyses only. In gender- and fully-ad-
justed analyses, higher cortisol and IL-8 were additional
predictors of lower ALM. Higher DHEAS was only asso-
ciated with lower ALM in gender-adjusted analysis.
Associations Between Baseline Inflammation
Markers and Sarcopenia at Follow-Up
Lower adiponectin:leptin ratios and elevated levels of CRP,
cortisol and IL-8 were associated with increased risk of
sarcopenia as defined by the EWGSOP algorithm at follow-
Table 1 Characteristics of 336
participants from the
Hertfordshire Cohort Study
Mean (SD) Men (n = 186) Women (n = 150) Obs
Age at HCS baseline clinic (years) 63.8 (2.5) 65.6 (2.7) 336
Follow-up time (years)a 11.6 (11.1, 11.9) 10.1 (9.8, 10.4) 336
Height (cm) 174.7 (6.5) 161.7 (5.5) 336
Weight (kg) 80.8 (11.0) 69.2 (12.2) 336
BMI (kg/m2) 26.5 (3.3) 26.4 (4.3) 336
Ever smokedb 113 (60.8%) 50 (33.3%) 336
Alcohol consumer (C 1 unit per week)b 166 (89.2%) 86 (57.3%) 336
Prudent diet score - 0.6 (2.0) 1.1 (1.8) 336
Dallosso physical activity score 65.0 (13.5) 63.0 (14.1) 336
Number of systems medicateda 1 (0, 1) 1 (0, 2) 336
CRP (mg/L)a 0.7 (0.4, 1.9) 1.1 (0.5, 2.3) 322
Adiponectin (ug/ml):Leptin (ng/ml) ratioa 0.6 (0.2, 1.5) 0.2 (0.1, 0.4) 322
IL-10 (pg/ml)a 7.0 (5.9, 10.6) 7.2 (5.9, 10.6) 334
IL-6 (pg/ml)a 6.2 (3.4, 8.8) 6.1 (3.1, 7.6) 286
Cortisol (ug/ml)a 0.10 (0.09, 0.12) 0.09 (0.08, 0.10) 331
DHEAS (ug/ml)a 1.1 (0.8, 1.5) 0.7 (0.5, 1.0) 333
TNF (pg/ml)a 4.7 (2.5, 11.6) 3.5 (2.9, 9.8) 323
IL-8 (pg/ml)a 7.5 (5.4, 10.5) 6.9 (5.8, 9.2) 268
Baseline grip strength (kg) 44.6 (7.2) 27.5 (5.2) 335
Grip change (kg/year) - 0.71 (0.48) - 0.58 (0.49) 335
Characteristics at follow-up
Grip strength (kg) 36.4 (7.4) 21.7 (6.1) 335
Appendicular lean mass (kg) 24.3 (2.8) 16.5 (2.2) 289
Appendicular lean mass index (kg/m2) 8.05 (0.75) 6.42 (0.72) 289
Walking speed (m/s) 0.79 (0.17) 0.74 (0.18) 314
EWGSOP sarcopeniab 12 (7.4%) 11 (8.7%) 289
Grip change annual change in grip from HCS baseline to 2011 follow-up, EWGSOP European Working
Group on Sarcopenia in Older People, Obs number of non-missing observations
aMedian (lower quartile, upper quartile)
bn (%)
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Table 2 SD difference (95% CI) in outcome at follow-up per SD increase in inflammatory predictor
Outcome Inflammatory predictor Gender-adjusted Fully-adjusteda
Estimate (95% CI) p value Estimate (95% CI) p value
Grip strength CRP - 0.21 (- 0.32, - 0.10) < 0.001 - 0.21 (- 0.32, - 0.10) < 0.001
Ad:lep ratio 0.05 (- 0.06, 0.16) 0.364 0.08 (- 0.03, 0.19) 0.135
IL-10 0.05 (- 0.06, 0.16) 0.354 0.03 (- 0.07, 0.13) 0.529
IL-6 - 0.02 (- 0.14, 0.10) 0.771 - 0.02 (- 0.13, 0.09) 0.725
Cortisol - 0.00 (- 0.11, 0.10) 0.930 0.00 (- 0.10, 0.11) 0.976
DHEAS - 0.04 (- 0.15, 0.06) 0.425 - 0.02 (- 0.12, 0.09) 0.738
TNF 0.03 (- 0.08, 0.14) 0.543 0.03 (- 0.07, 0.13) 0.587
IL-8 0.00 (- 0.12, 0.12) 0.945 0.06 (- 0.06, 0.17) 0.322
Grip strength change CRP - 0.15 (- 0.26, - 0.04) 0.006 - 0.13 (- 0.24, - 0.01) 0.030
Ad:lep ratio 0.02 (- 0.08, 0.13) 0.686 0.02 (- 0.09, 0.13) 0.734
IL-10 0.07 (- 0.04, 0.17) 0.221 0.06 (- 0.05, 0.16) 0.306
IL-6 0.07 (- 0.05, 0.19) 0.238 0.09 (- 0.03, 0.21) 0.122
Cortisol 0.08 (- 0.03, 0.19) 0.138 0.08 (- 0.03, 0.19) 0.132
DHEAS 0.03 (- 0.08, 0.14) 0.550 0.05 (- 0.06, 0.16) 0.386
TNF 0.05 (- 0.06, 0.16) 0.406 0.05 (- 0.06, 0.16) 0.374
IL-8 0.01 (- 0.11, 0.13) 0.891 0.03 (- 0.09, 0.15) 0.647
Walking speed CRP - 0.18 (- 0.29, - 0.07) 0.001 - 0.10 (- 0.22, 0.01) 0.085
Ad:lep ratio 0.15 (0.04, 0.26) 0.008 0.08 (- 0.04, 0.20) 0.200
IL-10 - 0.05 (- 0.16, 0.06) 0.348 - 0.07 (- 0.18, 0.03) 0.176
IL-6 - 0.01 (- 0.13, 0.11) 0.908 - 0.00 (- 0.12, 0.12) 0.965
Cortisol - 0.02 (- 0.14, 0.09) 0.720 - 0.06 (- 0.17, 0.06) 0.334
DHEAS - 0.01 (- 0.12, 0.10) 0.848 - 0.01 (- 0.12, 0.10) 0.875
TNF 0.01 (- 0.10, 0.12) 0.898 - 0.01 (- 0.12, 0.10) 0.894
IL-8 - 0.04 (- 0.16, 0.08) 0.478 - 0.04 (- 0.16, 0.08) 0.541
Appendicular lean mass CRP 0.13 (0.02, 0.25) 0.025 0.15 (0.05, 0.25) 0.002
Ad:lep ratio - 0.11 (- 0.23, 0.00) 0.055 - 0.05 (- 0.15, 0.05) 0.306
IL-10 0.04 (- 0.07, 0.16) 0.480 0.03 (- 0.06, 0.13) 0.503
IL-6 - 0.00 (- 0.13, 0.13) 0.984 - 0.07 (- 0.18, 0.04) 0.201
Cortisol - 0.12 (- 0.24, - 0.00) 0.042 - 0.10 (- 0.20, - 0.01) 0.039
DHEAS - 0.13 (- 0.25, - 0.01) 0.032 - 0.08 (- 0.18, 0.02) 0.107
TNF - 0.02 (- 0.14, 0.09) 0.700 - 0.06 (- 0.15, 0.04) 0.227
IL-8 - 0.19 (- 0.32, - 0.06) 0.005 - 0.11 (- 0.22, - 0.00) 0.043
EWGSOP sarcopeniab CRP 1.37 (0.90, 2.08) 0.144 1.77 (1.08, 2.90) 0.023
Ad:lep ratio 0.86 (0.61, 1.21) 0.387 0.62 (0.44, 0.87) 0.006
IL-10 1.06 (0.74, 1.51) 0.761 0.99 (0.74, 1.34) 0.969
IL-6 1.44 (0.78, 2.68) 0.246 1.27 (0.71, 2.28) 0.416
Cortisol 1.39 (1.08, 1.79) 0.011 1.35 (0.95, 1.91) 0.092
DHEAS 1.12 (0.75, 1.68) 0.576 1.11 (0.74, 1.64) 0.619
TNF 1.32 (0.87, 2.02) 0.194 1.31 (0.89, 1.94) 0.167
IL-8 1.57 (1.35, 1.84) < 0.001 1.37 (1.10, 1.71) 0.005
Separate regression models were fitted for each baseline inflammatory predictor
Sex-specific SD scores were derived for inflammatory predictors and continuous outcomes. Apart from IL-8, all inflammatory markers were log-
transformed prior to standardising
Unadjusted estimates correspond to Pearson correlations between inflammatory markers and outcomes (apart from sarcopenia)
Change in grip strength from HCS baseline to follow-up was obtained using a residual change method to ensure grip change measure was
independent of baseline grip level
Ad:lep ratio adiponectin:leptin ratio, EWGSOP European Working Group on Sarcopenia in Older People
Significant associations (p < 0.05) are in bold
aRegressionmodels adjusted for the following characteristics at baseline: gender, age, follow-up time, height, weight-for-height residual, smoking history
(ever vs never), alcohol consumption, diet quality and physical activity.Models for appendicular leanmasswere not adjusted forweight-for-height residual
and models for change in grip were not adjusted for follow-up time (follow-up time was already used to derive the grip change measure)
bEstimates are relative risks per SD increase in baseline inflammatory predictors. Relative risks were derived using Poisson regression models
with robust variance estimation
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up, although the strength of associations varied according
to the other covariates included in the models.
Discussion
Using data from the HCS, we have shown that indices of
inflammation are associated with each of the three com-
ponents of sarcopenia; muscle mass, muscle strength and
physical performance. The strongest associations were with
CRP and were robust to adjustment for gender and lifestyle
characteristics. Additional relationships were found with
IL-8, a principal member of the inflammatory cascade, and
cortisol, the most potent of the endogenous immunosup-
pressants. Fully-adjusted associations were similar when
additionally adjusted for number of systems medicated (a
marker of comorbidity) or steroid use. This study makes an
important contribution to the published literature by
examining the longitudinal associations between a wide
range of inflammatory markers, cytokines and adipokines,
with measures of muscle mass, strength, physical perfor-
mance, and sarcopenia.
Our study has some limitations. First, selection bias may
have affected our study at several stages. In common with
many epidemiological studies, a healthy responder bias has
been observed in HCS [11], however, baseline participants
remained broadly comparable with participants in the
nationally representative Health Survey for England [11].
In addition, sample attrition across the various waves of
follow-up (possibly owing to mortality, morbidity and
changes of address) could have resulted in further selection
effects. However, we have described participant charac-
teristics according to inclusion status across the study and
found no major differences. Furthermore, because our
analyses were internal, unless there was a systematic dif-
ference in the associations of interest among our study
participants and those who were invited to take part in the
study but did not, no major bias should have occurred.
Secondly, although a relatively small sample size was used,
the similarity between our findings and those of similar
studies is encouraging [8, 16]. Thirdly, the markers of
inflammation were measured at a single time point, which
could be influenced by concurrent illnesses. However, due
to the arrangement of the research clinics, it is unlikely that
participants would have attended if acutely unwell or
debilitated by long-term chronic disease. This is supported
by that fact that the majority of the inflammation markers
were within the normal range, suggesting that this was a
largely healthy population. It can, therefore, be assumed
that the inflammatory markers represent the inflammatory
phenotype of the participant within the cohort as a whole.
Fourthly, it is possible that the serum measurements of
cytokine levels may not be indicative of the cytokine
milieu at the level of the tissue of interest; muscle. Further
in vivo, tissue-level studies are required to investigate this
further. Finally, the availability of outcomes (other than
Fig. 2 SD difference (95% CI) in outcomes per SD increase in
inflammatory predictors. Ad:lep adiponectin:leptin ratio. Regression
models adjusted for the following characteristics at baseline: gender,
age, follow-up time, height, weight-for-height residual, smoking
history (ever vs never), alcohol consumption, diet quality and
physical activity. Poisson regression models with robust variance
estimation were used for EWGSOP sarcopenia status to yield relative
risks (RR). Models for ALM were not adjusted for weight-for-height
residual and models for change in grip were not adjusted for follow-
up time (follow-up time was already used to derive the grip change
measure). Adjusted p values are presented. Change in grip strength
from HCS baseline to follow-up was obtained using a residual change
method to ensure grip change measure was independent of baseline
grip level. A positive estimate illustrates that a higher level of the
inflammatory marker was associated with reduced loss of grip
strength and a negative estimate reflects accelerated loss. Apart from
IL-8, all inflammatory markers were log-transformed prior to
standardising
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grip strength) at baseline would have enabled investigation
of the association between inflammation and change in
muscle mass and function.
Our study also has many strengths. First, a residual
change method was used to calculate a measure of change
in grip strength which was independent of baseline grip
strength and free from the effect of regression to the mean.
Second, we examined the longitudinal associations
between a broad panel of inflammatory markers and sev-
eral defining components of sarcopenia with adjustment for
a wide range of potential confounders (however, we cannot
rule out the potential effects of unmeasured confounders).
Finally, the HCS provides a strong foundation for research
owing to: conduct of the fieldwork according to strict
protocol by trained research nurses; detailed phenotyping
of the cohort; and the continued management of the study
by an experienced multidisciplinary team.
C-reactive protein is a consummate marker of inflam-
mation, utilised ubiquitously in clinical practice and has
been much studied in relation to many conditions. It is
produced by the liver and rises up to 10,000-fold in
response to major tissue damage or severe infection [17].
However, outside of acute stimuli, the year to year, intra-
individual variation in CRP is stable [18] with a significant
association between baseline CRP and risk of vascular
disease and mortality from cardiovascular disease, cancer
and respiratory conditions [19]. This supports our use of a
single measurement of inflammatory marker as a surrogate
for overall, inflammatory phenotype. We found that a
higher CRP was associated with lower grip strength,
accelerated loss of grip strength, slower gait speed (in
gender-adjusted analyses only), and sarcopenia (in fully-
adjusted analyses only). Similar associations between
reduced physical performance and grip strength and
increasing CRP have been demonstrated in elderly Italian
[8] and Dutch [20] cohorts. Further replication is provided
by a previous study which demonstrated a graded associ-
ation between increased CRP and reduced grip strength
[21]. A similar, graded relationship between reduced CRP
and faster gait speed has been seen in a multi-national
study involving 64-74 year old participants from the North
and South American continents [16]. This would support
our finding of a negative association between CRP and
walking speed.
The mechanism by which the association of CRP with
parameters of muscle strength and function occurs is still
under investigation though, a primed, pro-inflammatory
environment, which would result in an increase in CRP as a
marker of inflammation, is associated with the process of
ageing, frailty and sarcopenia [22].
A raised CRP was also associated with greater ALM.
This may seem counterintuitive, as a higher inflammatory
burden would inhibit the anabolic processes involved in
muscle tissue formation. However, if we consider that
those with greater fat mass are also likely to have greater
muscle mass (as demonstrated by ALM), a raised CRP
would represent the increased inflammatory burden asso-
ciated with adipose tissue. This is supported by the fact that
CRP was not associated with ALM index when adjusted for
whole body fat mass index in our sample (data not shown).
Indeed, as adiposity increases, adipose tissue dysfunction
can occur. Lipids leak into the circulation and deposit in
muscle tissue leading to the localised production of reac-
tive oxygen species and an inflammatory response (the
latter of which will lead to a raised CRP). This can result in
damage to mitochondria, muscle tissue damage, and thus,
reduced muscle function.
Adipose tissue, besides its primary function as energy
storage, also plays significant roles in the determination of
the prevailing balance between pro- and anti-inflammatory
states in the body as a whole. Adiponectin, an anti-in-
flammatory adipokine, inhibits nuclear factor jB (NFjB)
leading to reduced macrophage activation, reduced TNF
and interferon gamma (IFNc) and increases IL-10 and
interleukin-1 receptor antagonist (IL-1RA). It is negatively
associated with fat mass and leptin [23], and levels reduce
with age [24]. On the other hand, leptin, a pro-inflamma-
tory adipokine, reflects adipose mass [25] and is associated
with the pro-inflammatory mediators; TNF, IL-6, inter-
leukin-12 (IL-12) and activates natural killer lymphocytes
[26]. In our study, we found that an increased adipo-
nectin:leptin ratio was associated with faster walking speed
(though this association was not robust beyond gender-
adjustment) and with reduced risk of sarcopenia. This is
explained by the fact that a higher adiponectin:leptin ratio
purports to represent a more anti-inflammatory adipokine
profile, which would fit with a reduced propensity to
muscle ageing and damage.
The negative associations of cortisol and IL-8 with
ALM are simply explained.
IL-8 is a rife chemotactic agent for neutrophils and
higher levels will represent a more primed, and active,
innate immune response. Neutrophil dysregulation,
including a reduced susceptibility to apoptotic signals and a
more limited response to chemotactic agents, occurs with
increasing age [27]. This is important in the process of
inflammaging (a low-level state of inflammation as a result
of an aged immune system) as delayed neutrophil transit
and increased dysregulation leads to the leakage of matrix
metalloproteinases and other enzymes leading to localised
tissue damage. If this process was to occur within muscle,
we would see a raised IL-8 in association with sarcopenia.
Certainly, an active immune response has previously been
associated with cachexia and frailty [22], so an association
with sarcopenia would be aetiologically coherent.
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In order to counteract inflammaging, the body embold-
ens the process of ‘anti-inflammaging’ in the form of anti-
inflammatory cytokine production and cortisol release.
Cortisol is the most potent, endogenous immunosuppres-
sive agent and production can be stimulated by interleukin-
1 (IL-1), IL-6 and TNF via the hypothalamo-pituitary axis.
However, as well as the anti-inflammatory effects [28], it
has direct effects of bone resorption, gluconeogenesis and
muscle catabolism. Higher levels of cortisol (as seen in the
cortisol to DHEAS ratio) have been associated with sig-
nificantly increased odds of frailty at 10-year follow-up
[29]. Thus, the association we observed between higher
cortisol and reduced ALM makes physiological sense and
could be demonstrative of an increased anti-inflammatory,
‘anti-inflammaging’ response.
In summary, our findings highlight an important role for
CRP, IL-8 and other elements of immune function in the
development of sarcopenia and its constituent components;
muscle strength, muscle mass and physical function. Fur-
ther work is required to delineate these relationships.
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